# Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

> **NCT02168829** · PHASE4 · COMPLETED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 1284 (actual)

## Conditions studied

- Atrial Fibrillation
- Stroke

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Acetylsalicylic acid

## Key facts

- **NCT ID:** NCT02168829
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-08-14
- **Target enrollment:** 1284 (ACTUAL)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168829, "Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02168829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*